Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1148 | Daily Monitoring Wiki | 1.00 |
| drug758 | COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002659 | Child Development Disorders, Pervasive NIH | 0.41 |
| D001321 | Autistic Disorder NIH | 0.30 |
| D000067877 | Autism Spectrum Disorder NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000717 | Autism HPO | 0.30 |
| HP:0000729 | Autistic behavior HPO | 0.27 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a brief, telehealth intervention (the Emotional Support Plan), intended to support autistic adults to cope with their negative emotions during and/or after the COVID-19 pandemic. The first objective is to develop and refine a brief telehealth-delivered treatment, the Emotional Support Plan (ESP), to help promote adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic. The second objective is to assess the feasibility and effectiveness of the ESP to support autistic adults to implement emotion regulation strategies during periods of acute distress. The last objective is to yield preliminary data to apply for extramural grants to validate these methods to monitor and support mental health of autistic adults during key transitions (e.g., starting college).
Description: The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more distress.
Measure: Decreased distress on Patient Health Questionnaire (PHQ-9) Time: 8 week study periodDescription: EMA (Ecological Momentary Assessment) reports of decreased distress (in ESP + daily monitoring group only). Higher scores on the item equal higher levels of distress.
Measure: Decreased distress on EMA reports Time: 8 week study periodDescription: The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a "0" (not at all) to "3" (nearly every day) scale. Higher scores equal more anxiety.
Measure: Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7) Time: 8 week study periodDescription: The ASR is a measure of adaptive functioning and psychopathology (e.g., anxiety, depression symptoms). Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.
Measure: Adult Self Report (ASR) Time: 8 week study periodAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports